Modulation of alveolar macrophage leukotriene B4 released by complement component C5.
The release of neutrophil chemotactic activity by the guinea pig alveolar macrophage (AM) is dependent on the fifth component of complement (C5) on the cell surface. Because one potent chemotactic factor released by AMs is leukotriene B4 (LTB4), we hypothesized that cell surface C5 may modulate LTB4 release. To test this hypothesis, human AMs obtained by bronchoalveolar lavage from 12 subjects were cultured for 4 hours in the presence of anti-C5 Fab' antibodies with stimuli. The cultures were harvested and evaluated for LTB4 by radioimmunoassay. The LTB4 levels in supernatants obtained from AMs cultured in media alone were variable (447 +/- 63 pg/ml), but the levels were increased when AMs were cultured with the stimuli-opsonized zymosan, immune complexes, or lipopolysaccharide (233%, 49%, and 114% increase, respectively, compared with macrophages cultured in media alone, p less than 0.05). Culturing the AMs with anti-C5 Fab' antibodies inhibited the release of LTB4 induced by opsonized zymosan, immune complexes, or lipopolysaccharide (78%, 41%, and 82% inhibition, respectively, p less than 0.05). Consistent with these observations, anti-C5 Fab' antibodies also decreased the neutrophil chemotactic activity of culture supernatants obtained from AMs stimulated with the same stimuli (p less than 0.001). These data suggest that AM release of LTB4 may be C5-dependent.
Robbins
R A
RA
Research Service, Omaha Veterans Administration Medical Center, NE.
Gossman
G L
GL
Allington
L A
LA
Kendall
T J
TJ
Stull
T W
TW
Rennard
S I
SI
D000906:Antibodies / Q000494:pharmacology; D000936:Antigen-Antibody Complex / Q000494:pharmacology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002478:Cells, Cultured; D003182:Complement C5 / Q000276:immunology / Q000502:physiology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D007975:Leukotriene B4 / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008262:Macrophage Activation / Q000187:drug effects; D008264:Macrophages / Q000378:metabolism*; D009895:Opsonin Proteins; D011650:Pulmonary Alveoli / Q000166:cytology; D015054:Zymosan / Q000494:pharmacology
D000906:Antibodies; D000936:Antigen-Antibody Complex; D003182:Complement C5; D007140:Immunoglobulin Fab Fragments; D008070:Lipopolysaccharides; D009895:Opsonin Proteins; D007975:Leukotriene B4; D015054:Zymosan